Summary
3.98 -0.39(-8.92%)06/14/2024
Absci Corp (ABSI)
Absci Corp (ABSI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -8.82 | -8.92 | -17.43 | -16.91 | 44.20 | 136.90 | 0.00 | -81.57 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.98 | |
| Open | 4.35 | |
| High | 4.37 | |
| Low | 3.92 | |
| Volume | 1,693,824 | |
| Change | -0.39 | |
| Change % | -8.82 | |
| Avg Volume (20 Days) | 1,259,431 | |
| Volume/Avg Volume (20 Days) Ratio | 1.34 | |
| 52 Week Range | 1.11 - 6.72 | |
| Price vs 52 Week High | -40.77% | |
| Price vs 52 Week Low | 258.56% | |
| Range | -8.51 | |
| Gap Up/Down | -0.85 | |
Fundamentals | ||
| Market Capitalization (Mln) | 510 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 26.25 | |
| Book Value | 4.1920 | |
| Earnings Per Share | -2.6840 | |
| EPS Estimate Current Quarter | -0.1900 | |
| EPS Estimate Next Quarter | -0.1900 | |
| EPS Estimate Current Year | -1.9400 | |
| EPS Estimate Next Year | -1.0300 | |
| Diluted EPS (TTM) | -2.6840 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.7017 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 6,058,000 | |
| Revenue per share TTM | 0.1940 | |
| Quarterly Revenue Growth (YOY) | 0.6800 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -6,668,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.4293 | |
| Revenue Enterprise Value | 113.0793 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 92,591,504 | |
| Shares Float | 42,481,893 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 17.08 | |
| Institutions (%) | 38.55 | |
05/28 08:00 EST - globenewswire.com
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
05/16 07:15 EST - investorplace.com
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
05/14 13:30 EST - seekingalpha.com
Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript
Absci Corporation. (NASDAQ:ABSI ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasson – Chief Financial Officer and Chief Business Officer Christian Stegmann – SVP of Drug Creation Conference Call Participants Kripa Devarakonda – Truist Securities George Farmer – Scotia Bank Jacqueline Kisa – TD Cowen Steve Dechert - KeyBanc Capital Markets Li Chen – H.C.
Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript
Absci Corporation. (NASDAQ:ABSI ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasson – Chief Financial Officer and Chief Business Officer Christian Stegmann – SVP of Drug Creation Conference Call Participants Kripa Devarakonda – Truist Securities George Farmer – Scotia Bank Jacqueline Kisa – TD Cowen Steve Dechert - KeyBanc Capital Markets Li Chen – H.C.
05/14 07:30 EST - globenewswire.com
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024.
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024.
05/07 10:16 EST - zacks.com
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
04/10 12:11 EST - zacks.com
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
03/21 07:30 EST - globenewswire.com
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.
03/01 16:01 EST - globenewswire.com
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million. All of the shares in the offering were sold by Absci.
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million. All of the shares in the offering were sold by Absci.
03/01 07:51 EST - zacks.com
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
02/27 22:20 EST - globenewswire.com
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $75.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $75.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.
02/27 16:01 EST - globenewswire.com
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci.
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci.
02/21 07:30 EST - globenewswire.com
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
02/05 10:43 EST - zacks.com
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
01/10 07:30 EST - globenewswire.com
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets.
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets.
01/03 08:00 EST - globenewswire.com
Absci to Participate in the 26th Annual Needham Growth Conference
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26th Annual Needham Growth Conference.
Absci to Participate in the 26th Annual Needham Growth Conference
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26th Annual Needham Growth Conference.
12/28 08:00 EST - globenewswire.com
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
12/20 07:30 EST - globenewswire.com
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
12/05 09:46 EST - zacks.com
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
12/04 07:30 EST - globenewswire.com
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development
12/03 01:28 EST - reuters.com
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.